Munjid Al Harthy

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer”.

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

British Journal of Urology(2020)10.1111/bju.15227

N/A

0DataRank · unranked

13 citations

Fatima Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen +22 more

Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5004

N/A

0DataRank · unranked

94 citations

Sandeep Gurram, Munjid Al Harthy, Eric A. Singer, Abhinav Sidana, Brian Shuch +14 more

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17046

N/A

0DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilušić +15 more